Extended thiopurine metabolite assessment during 6-thioguanine therapy for immunomodulation in crohn's disease

Journal of Clinical Pharmacology

Volumn 47, Issue 2, 2007, Pages 187-191

  De Boer, N K H ^a   Derijks, L J J ^b   Keizer Garritsen, J J ^c   Lambooy, L H J ^c   Ruitenbeek, W ^c   Hooymans, P M ^d   Van Bodegraven, A A ^a   De Jong, D J ^c  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MÁXIMA MEDICAL CENTER   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d Sittard Geleen Heerlen   (Netherlands)

Author keywords

6 Thioguanine; 6 thioguaninenucleotides; Crohn's disease; Metabolism; Pharmacology; Thiopurine; TPMT

Indexed keywords

MERCAPTOPURINE; TIOGUANINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL PRACTICE; CORRELATION ANALYSIS; CROHN DISEASE; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ERYTHROCYTE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOMODULATION; MALE; METABOLITE;

ADULT; CROHN DISEASE; ERYTHROCYTES; FEMALE; GUANINE NUCLEOTIDES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; THIOGUANINE; THIONUCLEOTIDES;

EID: 33846412914     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270006294403     Document Type: Article

References (19)

1. Al Hadithy AF, de Boer NK, Derijks LJ, Escher JC, Mulder CJ, Brouwers JR. Thiopurines in inflammatory bowel disease: pharmacogenetics, therapeutic drug monitoring and clinical recommendations. Dig Liver Dis. 2005 ; 37: 282-297.
2. de Jong D, Mulder CJ, van Sorge AA. Why measure thiopurine methyltransferase activity? Direct administration of 6-thioguanine might be the alternative for 6-mercaptopurine or azathioprine. Gut. 2001 ; 49: 874-874.
3. Dubinsky MC, Hassard PV, Seidman EG, et al. An open-label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6-mercaptopurine therapy. Inflamm Bowel Dis. 2001 ; 7: 181-189.
4. Derijks LJ, de Jong DJ, Gilissen LP, et al. 6-Thioguanine seems promising in azathioprine- or 6-mercaptopurine-intolerant inflammatory bowel disease patients: a short-term safety assessment. Eur J Gastroenterol Hepatol. 2003 ; 15: 63-67.
5. Dubinsky MC, Feldman EJ, Abreu MT, Targan SR, Vasiliauskas EA. Thioguanine: a potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine. Am J Gastroenterol. 2003 ; 98: 1058-1063.
6. Herrlinger KR, Deibert P, Schwab M, et al. Remission maintenance by tioguanine in chronic active Crohn's disease. Aliment Pharmacol Ther. 2003 ; 17: 1459-1464.
7. Deibert P, Dilger K, Fischer C, et al. High variation of tioguanine absorption in patients with chronic active Crohn's disease. Aliment Pharmacol Ther. 2003 ; 18: 183-189.
8. Tiede I, Fritz G, Strand S, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest. 2003 ; 111: 1133-1145.
9. Neurath MF, Kiesslich R, Teichgraber U, et al. 6-thioguanosine diphosphate and triphosphate levels in red blood cells and response to azathioprine therapy in Crohn's disease. Clin Gastroenterol Hepatol. 2005 ; 3: 1007-1014.
10. Keuzenkamp-Jansen CW, De Abreu RA, Bokkerink JP, Trijbels JM. Determination of extracellular and intracellular thiopurines and methylthiopurines by high-performance liquid chromatography. J Chromatogr B Biomed Appl. 1995 ; 672: 53-61.
11. Derijks LJ, Gilissen LP, Engels LG, et al. Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease: implications for therapy. Ther Drug Monit. 2004 ; 26: 311-318.
12. Keizer-Garritsen JJ, Brouwer C, Lambooy LH, et al. Measurement of thiopurine S-methyltransferase activity in human blood samples based on high-performance liquid chromatography: reference values in erythrocytes from children. Ann Clin Biochem. 2003 ; 40: 86-93.
13. Bean RHD. Treatment of ulcerative colitis with antimetabolites. Br Med J. 1966 ; 1: 1081-1084.
14. Lennard L, Davies HA, Lilleyman JS. Is 6-thioguanine more appropriate than 6-mercaptopurine for children with acute lymphoblastic leukaemia? Br J Cancer. 1993 ; 68: 186-190.
15. Derijks LJJ, Gilissen LPL, Engels LGJB, et al. Pharmacokinetics of 6-thioguanine in patients with inflammatory bowel disease. Ther Drug Monit. 2006 ; 28: 45-50.
16. Shipkova M, Armstrong VW, Wieland E, Oellerich M. Differences in nucleotide hydrolysis contribute to the differences between erythrocyte 6-thioguanine nucleotide concentrations determined by two widely used methods. Clin Chem. 2003 ; 49: 260-268.
17. Armstrong VW, Shipkova M, Von Ahsen N, Oellerich M. Analytic aspects of monitoring therapy with thiopurine medications. Ther Drug Monit. 2004 ; 26: 220-226.
18. McBride KL, Gilchrist GS, Smithson WA, Weinshilboum RM, Szumlanski CL. Severe 6-thioguanine-induced marrow aplasia in a child with acute lymphoblastic leukemia and inherited thiop-urine methyltransferase deficiency. J Pediatr Hematol Oncol. 2000 ; 22: 441-445.
19. Lancaster DL, Patel N, Lennard L, Lilleyman JS. 6-Thioguanine in children with acute lymphoblastic leukaemia: influence of food on parent drug pharmacokinetics and 6-thioguanine nucleotide concentrations. Br J Clin Pharmacol. 2001 ; 51: 531-539.